Outcomes of Relapsed or Refractory Diffuse Large B‐Cell Lymphoma Treated With R‐<scp>GemOx</scp>: A Multicenter Cohort Study
Samuel Yamshon(Cornell University), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Thomas M. Habermann(Mayo Clinic in Arizona), Peter Martin(Northwestern University), Connie Lee Batlevi(Memorial Sloan Kettering Cancer Center), Anthony Masaquel, Izidore S. Lossos(University of Miami), Dai Chihara(The University of Texas MD Anderson Cancer Center), Matthew J. Maurer(Mayo Clinic in Arizona), Grzegorz S. Nowakowski(Université Claude Bernard Lyon 1), Ashwini Shewade, Amy Ayers(The University of Texas MD Anderson Cancer Center), Carla Casulo(University of Rochester Medical Center), Michele Stanchina(Sylvester Comprehensive Cancer Center), Brad S. Kahl(UW Health University Hospital), Arushi Khurana(Mayo Clinic in Arizona), James R. Cerhan(Mayo Clinic), David Fox, Christopher R. Flowers(The University of Texas MD Anderson Cancer Center), Brian K. Link(University of Iowa), Jean L. Koff(Emory University), Tanner W. Reicks(Mayo Clinic in Florida), Umar Farooq(Wake Forest University), Yucai Wang(Mayo Clinic), Melissa C. Larson(Mayo Clinic), Yong Mun, Jonathon B. Cohen(Emory University), Andrea Lo‐Rossi, Sara Haddadi(University of Miami)
Cited by 10
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|10k
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents
|The Lancet|2016|2.8k
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k